Welcome to our dedicated page for Ovation news (Ticker: OVATF), a resource for investors and traders seeking the latest updates and insights on Ovation stock.
Ovation Science Inc. (OVATF) is a pharmaceutical research leader developing patented transdermal technologies for cannabis-based therapeutics. This news hub provides investors and industry stakeholders with essential updates on the company's licensing partnerships, product innovations, and market expansion strategies.
Access official press releases detailing advancements in InvisiCare® technology, regulatory milestones, and financial developments. Our curated collection features updates on North American market entries, research collaborations, and intellectual property achievements that demonstrate Ovation's leadership in cannabinoid delivery systems.
Key content includes earnings reports, partnership announcements with cannabis producers, and clinical research progress. Track the company's expansion through strategic licensing agreements in regulated markets while maintaining focus on compliant operations and scientific validation.
Bookmark this page for streamlined access to Ovation Science's corporate communications. Check regularly for updates on technological breakthroughs and business developments that shape the future of topical cannabis applications in medical and wellness markets.
Ovation Science Inc. has launched new high-dose CBD formulations in response to the growing CBD market. The company developed a transdermal cream with 1500mg of CBD per ounce and a beauty line offering 200mg per ounce for anti-aging creams and 2000mg for body lotion. The demand for high-dose CBD topicals is increasing, supported by a projected CAGR of 21.2% for CBD products from 2021 to 2028. Ovation aims to expand its market presence beyond Nevada, where its products rank among the top five in sales at dispensaries.
Ovation Science Inc. reported a 15% increase in royalty revenue due to strong sales of its topical cannabis products in Nevada. As of November 30, five of the top ten topical products sold in the state are from Ovation. The company is leveraging its patented Invisicare technology, which enhances the absorption of CBD and THC. Overall cannabis sales in the U.S. for 2021 are projected to reach nearly $31 billion, an increase of 41% over 2020. Ovation aims to expand its licensing model to other states and engage in consumer packaged goods (CPG) opportunities in the upcoming year.
Ovation Science Inc. (CSE:OVAT, OTCQB:OVATF) has announced a new partnership with Pivot Protection Resource, a national distributor for its DermSafe non-alcohol hand sanitizer lotion. This move aims to enhance workplace safety amid the ongoing pandemic, particularly with the rising prevalence of the Delta variant. DermSafe, which uses 4% chlorhexidine gluconate, offers superior germ protection without the drying effects of alcohol. It has shown a 99.97% reduction in the human coronavirus in tests and is recognized by the Canadian Dermatology Review Panel.
Ovation Science Inc. (CSE:OVAT, OTC:OVATF) reports a surge in sales of its non-alcohol hand sanitizer, DermSafe, to athletes across Canada. DermSafe, which contains 4% chlorhexidine gluconate, offers long-lasting germ protection without drying hands. It has shown a 99.97% reduction in the human coronavirus strain OC43. The product has received a Seal of Approval from the Canadian Dermatology Review Panel. Management emphasizes the necessity of such products as athletes return to sports.
Ovation Science Inc. (CSE:OVAT)(OTCQB:OVATF) has launched an online campaign to promote its DermSafe® hand sanitizer, which utilizes Invisicare® technology instead of alcohol. This initiative will feature over 100 articles on Canadian Skin Information's websites, attracting more than 25,000 monthly visitors. DermSafe, effective against COVID-19 with a 99.97% reduction in virus, addresses skin conditions such as dryness and eczema. The campaign aims to boost sales amid retail lockdowns in Canada, providing easy access for consumers.
Ovation Science Inc. has provided an update on its ongoing development of topical and transdermal cannabis products utilizing its patented Invisicare® technology. The company has developed over 30 products, including health and wellness and beauty items, with various CBD to THC ratios. They successfully established a strong market presence in Nevada and aim to expand into other U.S. states. The topical cannabis market is projected to reach $4.5 billion by 2025, marking a significant growth opportunity for Ovation and its unique formulation capabilities.
Ovation Science Inc. (CSE:OVAT)(OTCQB:OVATF) has announced progress in its topical and transdermal cannabis products using patented Invisicare technology. The company now has over thirty products developed, focusing on health, wellness, and beauty. Ovation aims to expand distribution beyond Nevada to other approved US states and is seeking partnerships with multi-state operators. The topical cannabis market is projected to grow to $4.5 billion by 2025, representing a 540% increase. The company has a strong reputation among consumers and budtenders in Nevada.
Ovation Science Inc. announced significant growth in its cannabis product sales, reporting a more than 70% increase in January 2021 compared to December 2020, marking the highest sales since February 2020. The company's royalty income also reached its highest level in the past year. Ovation focuses on topical and transdermal cannabis products, aiming to expand beyond Nevada. Their patented Invisicare technology enhances the absorption of CBD and THC. The broader acceptance of cannabis and increased tourism are expected to drive further growth.
Ovation Science Inc. reported a significant increase in sales through its Nevada licensee, with January 2021 sales surpassing December 2020 by over 70%. This marks the highest sales level since February 2020, reflecting a potential turnaround in the topical cannabis market. The company's royalty income has improved, and CEO Terry Howlett anticipates continued growth as the economy reopens. Ovation's patented Invisicare technology enhances cannabinoid delivery in its products, appealing to a broad market. The overall cannabis topicals segment is projected to reach $4.5 billion by 2025.
Ovation Science Inc. (CSE:OVAT)(OTCQB:OVATF) announced its U.S. listing on the OTCQB Market effective February 23, 2021, enhancing visibility to U.S. investors. The listing is part of Ovation's strategy to broaden its investor base amid increasing interest in the cannabis sector. Additionally, the company received DTC eligibility, facilitating electronic trading of its shares in the U.S. Ovation specializes in topical and transdermal cannabis products, supported by over 20 years of R&D and proprietary delivery technology.
